Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme

INTRODUCTION: Cognitive impairment (CI) is a major determinant of poor functional outcome in schizophrenia and there are currently no available pharmacotherapies. Deficits in glutamatergic signalling play a key role in the neuropathology of cognitive symptoms. Iclepertin (BI 425809), an inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales: Falkai, P., Reuteman-Fowler, C., Blahova, Z., Ikezawa, S., Marder, S. R., Krystal, J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661489/
http://dx.doi.org/10.1192/j.eurpsy.2023.1325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661489/
http://dx.doi.org/10.1192/j.eurpsy.2023.1325

Ejemplares similares